Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74:2913–21.
2. Siegel RL, Miller KD and Jemal A. Cancer Statistics, 2017. CA: a cancer journal for clinicians. 2017.
3. National Comprehensive Cancer Network. NCCN practice guidelines for pancreatic cancer, version 2. Available from: http://www.nccn.org/professionals/physician_gls/recently_ updated.asp.
4. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310:1473–81.
5. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, JASPAC 01 Study Group et al.. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016; 388:248–57.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献